Linked Life Data

11996326

Source:http://linkedlifedata.com/resource/pubmed/id/11996326

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2002-5-8
pubmed:abstractText
The aim of this study was to evaluate the long term effects of the selective Ca2+-blocker verapamil on atrial natriuretic peptide (ANP) levels in patients with moderate essential hypertension. The drug was given orally in a daily dose of 300 mg for 30 days. At the end of this clinical trial, plasma ANP levels increased by 16.14% despite the drop in blood pressure while left atrial and ventricular diameters remained unchanged. These findings indicate that the increase of ANP plasma levels is not the result of a mechanical load on the left cardiac chambers but the result of a pharmacological action. These observations also indicate that verapamil exerts part of its antihypertensive action by increasing ANP plasma levels.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0378-7966
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
45-8
pubmed:dateRevised
2011-2-2
pubmed:meshHeading
pubmed:articleTitle
Plasma atrial natriuretic peptide levels in essential hypertension after treatment with verapamil.
pubmed:affiliation
Departments of Second Cardiology, Medical School, Aristotle University of Thesssaloniki, Greece.
pubmed:publicationType
Journal Article